21 insiders reported 123 Form 4 transactions for Atrium Therapeutics, Inc. (RNA) over the past 18 months (most recent 2026-09-22). Recent activity: Boyce Sarah (Director) Sell 126,418 shares, Hughes Steven George (Chief Medical Officer) Sell 21,459 shares, Flanagan W. Michael (Director) Sell 22,812 shares, Gallagher Kathleen P. (Chief Executive Officer and President) Sell 11,632 shares, Kenney Stephanie (Chief Corporate Affairs Officer) Sell 2,375 shares. Source: SEC Form 4.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-22 | Boyce Sarah | Director | Sell | 126,418 | $1.1M |
| 2026-09-22 | Hughes Steven George | Chief Medical Officer | Sell | 21,459 | $192,058 |
| 2026-09-22 | Flanagan W. Michael | Director | Sell | 22,812 | $204,167 |
| 2026-09-22 | Gallagher Kathleen P. | Chief Executive Officer and President | Sell | 11,632 | $104,106 |
| 2026-09-22 | Kenney Stephanie | Chief Corporate Affairs Officer | Sell | 2,375 | $21,256 |
| 2026-09-22 | Winslow Brendan R. | Chief Financial Officer | Sell | 6,742 | $60,341 |
| 2026-09-22 | Hoyos Rocio Martin | Chief Strategy Officer | Sell | 8,320 | $74,464 |
| 2026-09-22 | Younis Husam | Chief Scientific Officer | Sell | 11,216 | $100,383 |
| 2026-04-22 | Winslow Brendan R. | Chief Financial Officer | Buy | 30,000 | $0 |
| 2026-04-22 | Younis Husam | Chief Scientific Officer | Buy | 30,000 | $0 |
| 2026-04-22 | Hoyos Rocio Martin | Chief Strategy Officer | Buy | 30,000 | $0 |
| 2026-04-22 | Kenney Stephanie | Chief Corporate Affairs Officer | Buy | 30,000 | $0 |
| 2026-04-22 | Hughes Steven George | Chief Medical Officer | Buy | 30,000 | $0 |
| 2026-04-22 | Gallagher Kathleen P. | Chief Executive Officer and President | Buy | 102,500 | $0 |
| 2026-01-23 | MacLean Michael F | Chief Financial Officer | Sell | 1,807 | $130,917 |
| 2026-01-23 | MacLean Michael F | Chief Financial Officer | Sell | 2,735 | $198,151 |
| 2026-01-23 | LEVIN ARTHUR A | Director | Sell | 1,758 | $127,367 |
| 2026-01-23 | McCarthy Teresa | Chief Human Resources Officer | Sell | 1,476 | $106,936 |
| 2026-01-23 | McCarthy Teresa | Chief Human Resources Officer | Sell | 1,453 | $105,270 |
| 2026-01-23 | Flanagan W. Michael | Chief Scientific Officer | Sell | 3,976 | $288,061 |
| 2026-01-23 | Flanagan W. Michael | Chief Scientific Officer | Sell | 2,558 | $185,327 |
| 2026-01-23 | Hughes Steven George | Chief Medical Officer | Sell | 2,017 | $146,132 |
| 2026-01-23 | Hughes Steven George | Chief Medical Officer | Sell | 2,878 | $208,511 |
| 2026-01-23 | Boyce Sarah | President and CEO | Sell | 6,394 | $463,245 |
| 2026-01-23 | Boyce Sarah | President and CEO | Sell | 7,993 | $579,093 |
Source: SEC Form 4 filings · as of 2026-09-22